Sunil Kumar/LinkedIn
Dec 17, 2025, 23:37
Sunil Kumar: Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024)
Sunil Kumar, Entrepreneur of Medifit Devices LLP, shared a post on LinkedIn:
“Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024).
Rare diseases may affect smaller patient populations, but strong science, high unmet need, and long term therapy adoption continue to translate into meaningful revenues. From enzyme replacement therapies to advanced coagulation factors, these products underline the commercial strength of rare disease portfolios.
The list highlights reported 2024 revenues along with primary approved indications across areas such as amyloidosis, hemophilia, and inherited metabolic disorders.”
Stay updated with Hemostasis Today.
-
Jul 28, 2026, 15:31Nancy Di Salvo: UNITAR and GBS|CIDP Foundation International Unite to Advance Plasma4Life
-
Jul 28, 2026, 15:30Alfonso J. Tafur: What Patients Fear Most When Anticoagulation Is Interrupted
-
Jul 28, 2026, 15:09John Perrier: Connecting Through Science at ISTH 2026
-
Jul 28, 2026, 15:00Rucha Patil: Grateful to Contribute to the National Coagulation Conclave 2026
-
Jul 28, 2026, 14:51Islam Aboumoussa: A New Perspective on Dual Antithrombotic Therapy in Stroke Prevention
-
Jul 28, 2026, 14:40Marilena Vrana: Join the Conversation at Plasma Protein Forum 2026
-
Jul 28, 2026, 14:24Jon Wright: Pushing the Boundaries of Hemophilia Care
-
Jul 28, 2026, 14:11Improving Care for People with Bleeding Disorders Through Teamwork – WFH
-
Jul 28, 2026, 14:10Blessing Oluwasanya: When Heavy Periods Are More Than Just an Inconvenience